Unlocking the Value of your Clinical Study
Friday, May 31, 2024 08:00 AM - 09:00 AM
Room 212-214
From FIH to Clinical Acceleration
Concurrent Session
Chair
The current early clinical trials landscape for Advanced Therapy Medicinal Products is growing, but progression into later clinical stages is stumbling across several challenges, with investment being one of them. In such a novel and complex field, where product benefit-risk balance is still uncertain, being able to generate compelling data to persuade and assure public and private investors is vital. In this session, we will focus on investment challenges and opportunities and discuss ways to increase the value of clinical studies while maximising funding odds and successful progression towards patient access.
- Sven Kili, MBChB, MRCS (Eng), CCRM, OmniaBio, United Kingdom
- Patrick Rivers, MBA, Aquilo Capital Management, United States, "Leveraging Early Clinical Results for Effective Fundraising"
- Daniella Kranjac, ChEng, MBA, Avant Bio, United States, "Tx-Enabling Technologies and their Role in Advancing Programs"
- Sven Kili, MBChB, MRCS (Eng), CCRM, OmniaBio, United Kingdom, "Ensure Your Early Clinical Planning Informs Commercialization and Fundraising Goals"
The current early clinical trials landscape for Advanced Therapy Medicinal Products is growing, but progression into later clinical stages is stumbling across several challenges, with investment being one of them. In such a novel and complex field, where product benefit-risk balance is still uncertain, being able to generate compelling data to persuade and assure public and private investors is vital. In this session, we will focus on investment challenges and opportunities and discuss ways to increase the value of clinical studies while maximising funding odds and successful progression towards patient access.
